Efficacy of a Novel Home-Based Stretching Program on Fibromyalgia Symptoms: A Randomized Controlled Trial.

Arch Phys Med RehabilJun 3, 2026 (epub)
Clinical ResearchPhysical Medicine & Rehabilitation

Morten Pallisgaard Støve, Stig Peter Magnusson, Janus Laust Thomsen et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a 6-week home-based low-intensity stretching program for fibromyalgia patients. Among 58 adults, the intervention group showed a significant reduction in the Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score, decreasing by 9.7 points (18.7% improvement) compared to a nonsignificant change in the control group.

Key findings

  • The intervention group experienced a mean FIQ-R total score decrease of 9.7 points.
  • The improvement in the intervention group was 18.7%, compared to a 0.8-point change in the control group.
  • The average adherence rate to the stretching program was 83%.
  • A significant group-by-time interaction was observed (F[1,56]=11.30; P<.001).

Why it matters

This study highlights the potential of a low-intensity stretching program as an effective nonpharmacological treatment for fibromyalgia, addressing adherence issues commonly seen with other interventions.

Source

PubMed · PMID 42242521

Published in Arch Phys Med Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.